Non-Small Cell Lung Cancer Stage IV Clinical Trial
Official title:
A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
The main purpose of this study is to evaluate the effectiveness of the study drug known as abemaciclib versus docetaxel in participants with stage IV squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02047344 -
Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC
|
Phase 2 | |
Terminated |
NCT00766246 -
Phase II Avastin Trial for Stage IIIB/IV NSCLC
|
Phase 2 | |
Active, not recruiting |
NCT04108026 -
Immunotherapy in Patient With Poor General Condition
|
Phase 2 | |
Active, not recruiting |
NCT04432207 -
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05598853 -
Intrathecal Double Checkpoint Inhibition
|
Phase 1 | |
Not yet recruiting |
NCT06117644 -
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
|
||
Terminated |
NCT01348126 -
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT01086254 -
SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT01798485 -
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
|
Phase 3 | |
Recruiting |
NCT06348199 -
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Not yet recruiting |
NCT06436144 -
Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC
|
Phase 2 | |
Terminated |
NCT04289259 -
Tumor Mutational Burden in Lung Cancer Patients
|
||
Active, not recruiting |
NCT05818449 -
Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet)
|
N/A | |
Completed |
NCT03526900 -
Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis
|
Phase 2 | |
Not yet recruiting |
NCT06463665 -
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer (VIRO-25)
|
Phase 2 | |
Completed |
NCT02176369 -
Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial
|
Phase 2 | |
Terminated |
NCT03275597 -
Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition
|
Phase 1 | |
Active, not recruiting |
NCT05055167 -
Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC
|
Phase 2 | |
Not yet recruiting |
NCT03543683 -
Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
|
||
Not yet recruiting |
NCT03532698 -
Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
|